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A B S T R A C T
Objectives: We evaluated trends in hypertension prevalence, awareness, treatment and control in an
Indian urban population over 25 years. Trends were projected to year 2030 to determine attainment of
World Health Organization (WHO) Global Monitoring Framework targets.
Methods: Adult participants (n = 7440, men 4237, women 3203) enrolled in successive population based
studies in Jaipur, India from years 1991 to 2015 were evaluated for hypertension prevalence, awareness,
treatment and control. The studies were performed in years 1991–93 (n = 2212), 1999–01 (n = 1123),
2003–04 (n = 458), 2006–07 (n = 1127), 2009–10 (n = 739) and 2012–15 (n = 1781). Descriptive statistics
are reported. We used logarithmic forecasting to year 2030 and compared outcomes to WHO target of
25% lower prevalence and >50% control.
Results: The age-adjusted hypertension prevalence (%) among adults in successive studies increased from
29.5, 30.2, 36.5, 42.1, 34.4 to 36.1 (R2 = 0.41). Increasing trends were observed for hypertension awareness
(13, 44, 49, 44, 49, 56; R2 = 0.63); treatment in all (9, 22, 38, 34, 41, 36; R2 = 0.68) and aware hypertensives
(61, 66, 77, 79, 70, 64; R2 = 0.46); and control in all (2, 14, 13, 18, 21, 21; R2 = 0.82), aware (12, 33, 27, 46, 37,
37; R2 = 0.54) and treated (9, 20, 21, 48, 36, 49; R2 = 0.80) hypertensive participants. Projections to year
2030 show increases in prevalence to 44% (95% CI 43–45), awareness to 82% (81–83), treatment to 62%
(61–63), and control to 36% (35–37).
Conclusion: Hypertension prevalence, awareness, treatment and control rates are increasing among
urban populations in India. Better awareness is associated with greater control. The rates of increase are
off-target for WHO Global Monitoring Framework and UN Sustainable Development Goals.
© 2017 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The United Nations (UN) has focused on increasing burden of
non-communicable disease (NCDs) in middle- and low-income
countries and has called for reducing this burden. In response, the
World Health Organization (WHO) has committed to reducing
premature mortality from NCDs by 25% by the year 2025 in its
25  25 target.1 WHO has proposed comprehensive plan to reduce
smoking and tobacco use, harmful alcohol use, salt intake, physical
inactivity, and elevated blood pressure and glucose levels to reduce* Corresponding author at: Department of Medicine, Eternal Heart Care Centre an
Research Institute, Jagatpura Road, Jawahar Circle, Jaipur 302017, India.
E-mail address: rajeevgg@gmail.com (R. Gupta).
https://doi.org/10.1016/j.ihj.2017.11.011
0019-4832/© 2017 Published by Elsevier B.V. on behalf of Cardiological Society of India. Th
org/licenses/by-nc-nd/4.0/).the risk of premature mortality from NCDs under the NCD Global
Monitoring Framework (NCD-GMF).2 Among the NCDs, the most
important target is reduction in mortality from cardiovascular
disease (CVD) and WHO has proposed, and participating countries
have agreed, for relative reduction in tobacco use by 30%, harmful
alcohol intake by 10%, salt consumption by 30%, prevalence of
hypertension by 25%, control of CVD risk factors in at least 50% and
stem the rising tide of obesity and diabetes.2 Lately, the UN has
adopted the sustainable development goals (SDGs) and the goal
number 3, target number 4 aims for a 33% reduction of NCD
mortality by 2030.3 It has been estimated that achievement of
these goals will require substantial reductions in CVD, which is the
leading cause of premature NCD mortality and accounts for over
half of all NCD-related deaths.4–6is is an open access article under the CC BY-NC-ND license (http://creativecommons.
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from smoking cessation, is blood pressure (BP) control.6,7 BP
control is poor worldwide. Prospective Urban Rural Epidemiology
(PURE) study evaluated hypertension awareness, treatment and
control in 17 countries at various stages of economic development
and reported that control was about 50% in high income countries
and less than 10% in lower middle income and low income
countries.8 Studies in USA and Western Europe have reported
increasing hypertension control over the last 50 years.9 US Joint
National Committee-7 reported that hypertension treatment and
control was about 25–30% in mid-sixties and increased to more
than 70% in recent years.10 Similar data were reported by National
Health and Nutrition Evaluation Surveys (NHANES) from 1988 to
2008.11 The NHANES studies from 1999 to 2012 reported that while
prevalent hypertension was unchanged during these years
(30–31%), increase was observed in hypertension treatment (from
60% to 75%) and its control especially among the treated (from 53%
to 69%).12 Similar rates of hypertension treatment and control have
been reported from many Western European and some high-
income countries.8,9
There is limited information on status of hypertension control
in low and lower-middle income countries.13 In India, studies have
reported low hypertension treatment and control rates in various
parts of the country, lower in rural than in urban.14–16 Anchala et al
performed a meta-analysis of studies that reported hypertension
awareness, treatment and control.14 Low rates of hypertension
awareness, treatment and control, respectively, were calculated in
urban (42%, 38% and 20%) as well as rural areas (25%, 24% and
11%).14 South Asian cohorts in PURE study reported similar low rate
of hypertension awareness, treatment and control, respectively, in
urban (46%, 38% and 15%) as well as rural (33%, 24% and 9%)
locations.17 Only a few studies in India have reported on changes in
hypertension prevalence using serial studies,18–21 however, time-
trends in hypertension treatment and control using multiple
studies with uniform methodology has not been performed. We
prospectively performed multiple cross sectional studies among
urban population in Jaipur, India, over the past 25 years to assess
prevalence of various cardiovascular risk factors.22–27 We reported
increasing trends in cardiometabolic risk factors such as obesity,
abdominal obesity, metabolic syndrome, diabetes and hypercho-
lesterolemia.28 A stable trend in hypertension prevalence was
observed in these studies.28 To determine trends in hypertension
awareness, treatment and control over the 25-year period we
performed the present study. We then projected these trends in
hypertension prevalence, awareness, treatment and control to
assess whether Indian populations are poised to achieve the
hypertension control target of 50% proposed by WHO Global
Monitoring framework.2
2. Methods
We performed a series of cross sectional epidemiological
studies in Jaipur in western India (Jaipur Heart Watch, JHW) in the
last 25 years to determine cardiovascular risk factors in urban
participants.22–27 All the studies were approved by institutional
ethics committees and supported financially by different orga-
nizations. The first study (JHW-1) was conducted in years 1992–
1994. This study was designed to investigate people at random and
to cover large and varied areas of this city with the intention of
including a wide range of urban subjects.22 Jaipur is divided into 70
municipal wards. Randomly chosen wards from different regions of
the city were identified to cover different socioeconomic groups.
Details of adult populations in those wards were available from the
voters’ lists. The total adult population in each ward varied from
15,000 to 30,000. The male:female ratio of Jaipur residents >20
years old is 1000:865. We randomly selected 500 persons (268men, 232 women) from each locality from the list of voters. When
the random number corresponded to the individual <20 years of
age it was assigned to the next person on the list. The target study
sample was 3000 with a population-proportionate male:female
ratio, thus 1609 men and 1391 women were invited to participate.
Formula for calculation of sample size is based on WHO
recommendations and reported earlier.22 In the second urban
study (JHW-2) we targeted 950 men and 850 women in the same
locations as in JHW-1 and could examine 1123 participants (62.4%,
men 550 men, women 573).23 In this study we targeted all the
participants for the fasting blood sample. The third (JHW-3), fourth
(JHW-4), fifth (JHW-5) and sixth (JHW-6) studies were in middle-
SES location-specific studies targeted at a smaller sample in the
above three municipal wards24–27 or in specific endogamous
ethnic communities.24,27 The sample sizes were derived using
WHO guidelines to estimate differences in risk factor prevalence.29
2.1. Data collection
Methodological details have been reported earlier.22 A detailed
proforma was utilized for data collection. Briefly, we collected
information regarding demographic data, history of major illnesses
such as coronary heart disease, hypertension, diabetes or high
cholesterol levels, and smoking or tobacco intake. Brief questions
were asked to evaluate physical activity and diet but the results
were considered inadequate and not included in various analyses.
Physical examination was performed to assess height, weight,
waist and hip size and BP using previously reported methodolo-
gy.30 BP was measured in sitting position using calibrated mercury
instruments. Three readings were obtained at 5 min intervals and
lowest value retained. We also obtained data on body mass index
(BMI), and fasting blood glucose and total cholesterol, high density
lipoprotein (HDL) cholesterol, triglycerides and low density
lipoprotein (LDL) cholesterol. Internal and external quality control
was maintained in all the studies to ensure uniformity of
methodology.
2.2. Diagnostic criteria
Hypertension was diagnosed when systolic BP was 140 mm
Hg and/or diastolic BP  90 mm Hg or a person was a known
hypertensive. Hypertension awareness status was estimated as
proportion of all participants with hypertension (BP  140 and/or
90 mm Hg) who were aware of their hypertensive status having
been diagnosed before by a physician or any other healthcare
provider. Treatment status was defined as (a) proportion of overall
hypertensive participants on drug treatment or (b) aware/known
hypertensive participants on treatment. Hypertension control was
defined as BP < 140 mm Hg systolic and <90 mm Hg diastolic and
determined as percentage of (a) all participants with hypertension,
(b) participants with known hypertension and (c) hypertensive
participants on drug treatment.29 Diagnostic criteria for other
cardiovascular risk factors such as tobacco use and smokers,
overweight and obesity, abdominal obesity, dyslipidemia and
diabetes have been reported.28
2.3. Statistical analyses
Prevalence rates are reported in percent. Age-specific preva-
lence rates have been determined for decadal intervals from 20 to
70+ years. Age-adjustment of various prevalence rates has been
performed by direct method using the WHO standard world
population.29 Hypertension awareness, treatment and control
rates are in percent. Age-adjustment of these rates has not been
performed. Significance of trends in hypertension prevalence,
awareness, treatment and control rates has been determined using
Table 1
Participants enrolled in various Jaipur Heart Watch studies.
Study Years performed Year reported [Reference] Target sample Participants enrolled
Men Women Men Women Total
JHW-1 1991–1994 199521 1600 1400 1415 797 2212
JHW-2 1999–2001 200222 950 850 550 573 1123
JHW-3 2003–2004 200423 320 280 226 232 458
JHW-4 2006–2007 200724 750 650 556 571 1127
JHW-5 2009–2011 201225 600 500 451 288 739
JHW-6 2012–2014 201526 1250 1250 1039 742 1781
JHW: Jaipur Heart Watch.
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awareness, treatment and control to the year 2030 have been
performed using data of all the JHW studies (JHW-1–JHW-6).
Projections were performed with Microsoft Excel software with
the trend analysis command. Forecasting to the year 2030 was
performed using logarithmic trend estimations within this
program. 95% confidence intervals (CI) were calculated using
Newcombe’s method.31 Two-tailed p values less than 0.05 have
been considered significant.
3. Results
Total participants in various Jaipur Heart Watch studies are
7440 (men 4237, women 3203). In all the studies men outnumber
women and age-group specific details are shown in Table 1. Age-
group specific hypertension prevalence is reported in Table 2.
There is a significantly increasing trend in hypertension preva-
lence. Age- and sex-adjusted hypertension prevalence in succes-
sive studies was 29.5%, 30.2%, 36.5%, 42.1%, 34.4% and 36.1%
(R2 = 0.41, ptrend< 0.001).
Trends in hypertension awareness show significant increase
from 13% in JHW-1 to more than 45% in later studies (Fig. 1).
Unadjusted awareness rates are 13%, 44%, 49%, 44%, 49% and 56%
(R2 = 0.63). Trends in hypertension treatment among all partic-
ipants with hypertension increased from 9% in JHW-1 to 22%, 38%,
34%, 41% and 36% in JHW-2–JHW-6 studies (R2 = 0.45). Among
participants with known hypertension it increased from 61% in
JHW-1 to 66%, 77%, 79%, 70% and 64% in JHW-2–JHW-6 studies
respectively (R2 = 0.45) (Fig. 2). Significantly greater proportion of
hypertension patients received treatment if they were aware of it
(Fig. 2). Hypertension control was low among all hypertensive
participants but increased from 2% in JHW-1 to 14%, 13%, 18%, 21%
and 21% (R2 = 0.85) over the 25-year period (Fig. 1). Trends in
hypertension control were significantly greater among aware
hypertensive participants: 12% to 33%, 27%, 46%, 37% and 37%
(R2 = 0.45) and treated hypertensives: 9% to 20%, 21%, 48%, 36% and
49% (R2 = 0.45) (ptrend< 0.001) (Fig. 2).
Projections for hypertension prevalence, awareness, treat-
ment and control to the year 2030 using data from all JHW
studies and logarithmic forecasting are shown in Fig. 3.
Hypertension prevalence would increase to 44% (95% CI, 43–
45%) in year 2030, a relative increase by 17%, instead of aTable 2
Hypertension prevalence at various age-groups in the JHW studies.
JHW-1 JHW-2 JHW-2 JHW-4 JHW-5 JHW-6
Years 1991–94 1999–01 2003–04 2006–07 2009–11 2012–14
20–29 10.9 10.2 14.1 20.7 22.7 16.2
30–39 20.9 25.7 34.6 36.2 19.6 27.5
40–49 34.8 40.3 57.0 63.3 36.8 41.4
50–59 61.6 54.5 74.4 67.7 54.9 60.0
60–69 55.7 59.0 77.6 72.2 64.2 67.9
70+ 49.5 67.4 84.6 82.2 65.2 72.5
JHW: Jaipur Heart Watch.relative decline by 25% by the year 2030 proposed by WHO.2
Calculations also show that hypertension awareness would
increase to 82% (95% CI 81–83%) (logarithmic regression
equation, y = 3426.9ln(x)  26014), treatment rate to 62% (95%
CI 61–63%) (y = 2851.9ln(x)  21655) and control to 36% (95% CI
35–37%) (y = 1800.9ln(x)  13679) (Fig. 3). WHO Global Moni-
toring Framework has recommended hypertension control in at
least 50% patients with raised BP by the year 2025 to achieve
cardiovascular disease control targets for UN Sustainable
Development Goals.1,3 The projections from the present study
are significantly lower at 36% (p < 0.01).
4. Discussion
Hypertension prevalence has increased among an Indian urban
population over the past 25 years. The rates of hypertension
awareness, treatment and control are also increasing. This study
also shows that better hypertension awareness is associated with
greater hypertension treatment and its control. Increasing
hypertension is opposite to targets of WHO Global Monitoring
Framework.2 The increase in treatment and control rates are also
lower than the proposed WHO targets. As this study is confined to
an urban Indian population we cannot extrapolate the data to rural
India where no similar studies exist. Previous Indian studies have
reported that hypertension prevalence is increasing more rapidly
in rural as compared to urban Indian populations.15 Therefore the
prevalence of hypertension could be greater in rural populations in
the next 15 years, a situation similar to high and middle income
countries.8 Studies have also reported that hypertension treatment
and control rates are 50% lower in rural than in the urban Indian
populations14 and therefore the control would be lower than in the
present study.
There are only limited studies in India that have reported
changes in hypertension prevalence using prospective cross-
sectional study design. Ahlawat et al. reported changes in
prevalence of various cardiovascular risk factors in Chandigarh
(North India) over a 30-year period.18 Age and sex adjusted
prevalence of hypertension according to current criteria increased
from 27% in 1968 to 45% in 1997. In Vellore (South India) studies in
rural and urban populations were performed in 1991–94 and
2010–12 to assess changes in cardiovascular risk factors.19 In rural
populations there was a doubling of hypertension while in the
urban it increased by 50%. Age-adjusted prevalence of hyperten-
sion in rural population increased in men from 8% to 17% and in
women from 7% to 12% while in urban populations the increase
was in men from 20% to 27% and in women from 17% to 22%. Goyal
et al. reported changes in risk factors in a rural Punjab population
over a 20 year period from 1994 to 2012 and reported increase in
hypertension prevalence from 15% to 27%.20 Roy et al reported
changes in hypertension prevalence in Delhi and National Capital
Region of India in urban and rural populations in 1991–94 and
2010–12.21 Hypertension prevalence increased in both popula-
tions, in urban from 23% to 42% and in rural from 11% to 29%.
Similar increase in hypertension prevalence has been observed in
Fig. 1. Trends in hypertension awareness, treatment and control in successive Jaipur Heart Watch studies. Data are in percent.
Fig. 2. Hypertension treatment and control rates (%) in participants who are aware of the hypertensive status in successive Jaipur Heart Watch studies.
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change in hypertension prevalence has followed an uneven course
and the difference in the age- and sex-adjusted prevalence in JHW-
1 and JHW-6 studies in 29.5%–36.1%, a relative increase of +22%.
This is lower than the urban studies from Chandigarh (+67%),
Vellore (men +36%, women, +30%) and Delhi (+83%) and much
lower than rural studies in Punjab (+102%), Vellore (men +115%,
women 64%) and Delhi (+158%). Roy et al did not observe an
increase in hypertension awareness, treatment and control rates in
and around Delhi.21 This is in contrast to the present study where
increasing trend in hypertension awareness, treatment and control
is observed (Fig. 3).
NCDRiSC (NCD Risk Factor Collaboration) investigators studied
changes in mean systolic BP and hypertension prevalence in
various parts of the world including South Asian countries and
India using multiple data sources.32 It was reported that
hypertension prevalence in India increased from 1980 to 2015 inmen from 24% to 28% (+16.7%) and in women from 22% to 27%
(+22.7%). These results are not dissimilar to our study. Projected
increase in hypertension by +17% in our urban population is
contrary to the stated goals of WHO Global Monitoring Framework
who advise a relative reduction in hypertension prevalence of
25%.2 Increase of hypertension in low and lower-middle income
developing countries has been attributed to multiple factors.13,16
Studies have reported that this is likely due to combination of
demographic and epidemiological transition, changing lifestyles
with increase in dietary fat and salt, low physical activity and
increasing obesity and abdominal obesity.13,16,33 Studies have
reported that social determinants of health, such as urbanization
and higher wealth and educational status in India are associated
with greater hypertension prevalence.17 There has been a rapid
increase in overweight and obesity in India in the last 20 years and
this correlates well with the increasing hypertension preva-
lence.34,35 In a previous JHW study report we have shown that
Fig. 3. Projections for hypertension prevalence, awareness, treatment and control rates among all hypertensive participants for the year 2030 using logarithmic forecasting
from Jaipur Heart Watch studies.
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correlated significantly with the increasing hypertension preva-
lence.36
Awareness, treatment and control of hypertension is gradually
increasing in India although there are large rural-urban dispar-
ities.14,15 Anchala et al performed meta-analysis of hypertension
epidemiology articles in India from 1953 to 2015.14 Overall
estimates for rates of awareness, treatment, and control of
hypertension were 42.0% (35.2–48.9), 37.6% (24.0–51.2), and
20.2% (11.6–28.7) for urban Indians and 25.3% (21.4–29.3), 25.1%
(17.0–33.1), and 10.7% (6.5–15.0) for rural Indians. Similar urban-
rural differences have been reported from other low-income
countries.37 The WHO Study on Aging and Global Health (SAGE)
evaluated hypertension prevalence, awareness, treatment and
control in older adults >50 years of age.38 Hypertension prevalence
was 32.3% in the Indian cohort (similar in urban and rural
participants in this study)38 but awareness, treatment and control
rates were similar to the present study. In our study, a slow
increase in awareness, treatment and control is a cause of concern.
Moreover, as our study is confined to urban Indians, it is likely that
the rates of hypertension awareness, treatment and control would
be lower in rural populations as reported in previous studies.14,39
The current rates of hypertension awareness and control in this
urban population of India are similar to the data in US about 50
years ago.40 More studies are needed to identify hypertension
control trends in populations from low- and lower-middle income
countries.A number of measures are available for increasing hypertension
treatment and control in India and other low income
countries.9,10,16,41,42 Increasing awareness of hypertension with
screening programs leads to greater chances of treatment and
better control of hypertension.42 Similar findings are observed in
the present study. Treatment and control rates in those of are
aware of the hypertension are double to those not aware (Fig. 2).
Other interventions to improve hypertension control include
policy-level, health system-level, population-level and clinic based
individual-level interventions. Policy and system level interven-
tions should be focused on public education and screening, while
population level interventions should focus on reduced intake of
salt and alcohol, smoking cessation, promotion of healthy diet and
facilitation of physical activity. Individual level interventions
should be on better physician education who should promote
individual lifestyle changes, appropriate pharmacotherapy and
control of vascular risk factors along with efforts to improve
adherence.41–43 Million Hearts Initiative in the US is focused on
increasing hypertension control using policy, population level and
clinic-based interventions.44 Similar program needs to be devel-
oped in India and other lower middle income countries to reduce
hypertension related cardiovascular morbidity and mortality.
This study has strengths and limitations. Strengths include a 25-
year span of multiple cross-sectional studies, similar locations and
use of uniform methodology in all the studies. Some of the
limitations such as nation-wide validity and applicability in
absence of rural data and fluctuating hypertension prevalence
(Table 2) have already been highlighted. Other limitations are lack
R. Gupta et al. / Indian Heart Journal 70 (2018) 802–807 807of a single cohort prospective study, variable sample sizes, low
female representation, variability in structure of communities and
locations, no data on causes for increase in hypertension in each
study, and lack of data on causes for low rates of awareness,
treatment and control of hypertension. Increasing hypertension
treatment and control is important for achieving the WHO Global
Monitoring Framework targets for delivering UN Sustainable
Development Goals in India. The SDG goal number 3 is focused
on health and section 3.4 has recommended reduction in NCD
related mortality by one-third through prevention and treatment
strategies. To achieve this goal it would be important to focus on
better control of hypertension in India.
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